Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Phase 3 Tuberculosis Trials

10 Phase 3 trials for Tuberculosis. Phase 3 trials are the final stage of testing before a treatment can be submitted for FDA approval.

What is a Phase 3 trial?

Phase 3 clinical trials study a treatment in large groups (hundreds to thousands of people) to confirm its effectiveness, monitor side effects, and compare it to standard treatments. These trials are the last major step before the FDA considers approving a new treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
RECRUITINGPhase 3NCT06905522

A PAN-USR TB Multi-Center Trial

Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the...

Sponsor: Shenzhen Third People's HospitalEnrolling: 6103 locations
RECRUITINGPhase 3NCT07209761

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

This study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant...

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 53220 locations
RECRUITINGPhase 3NCT04145258

Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from...

Sponsor: ANRS, Emerging Infectious DiseasesEnrolling: 76813 locations
RECRUITINGPhase 3NCT06057519

Pragmatic Optimized Rifampicin Trial

The goal of this clinical trial is to compare an optimized dose (1800 mg) of rifampicin to standard dose (450 mg if patient \<50 kg and 600 mg if patient \>50kg) of rifampicin in...

Sponsor: Radboud University Medical CenterEnrolling: 1642 locations
RECRUITINGPhase 3NCT05473520

Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis...

Sponsor: National University Hospital, SingaporeEnrolling: 1506 locations
RECRUITINGPhase 3NCT06253715

Shortened Regimen for Drug-susceptible TB in Children

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of...

Sponsor: Johns Hopkins UniversityEnrolling: 8609 locations
RECRUITINGPhase 3NCT05081401

Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant...

The INSPIRE-TB study is a pragmatic, multicentre, randomised, controlled, non-inferiority open-label trial to evaluate the efficacy and safety of seven 9-month oral regimens...

Sponsor: Huashan HospitalEnrolling: 10505 locations
RECRUITINGPhase 3NCT04975178

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy...

Sponsor: Biofabri, S.LEnrolling: 71201 location
RECRUITINGPhase 3NCT06497465

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy...

Sponsor: Johns Hopkins UniversityEnrolling: 1506 locations
RECRUITINGPhase 3NCT06727864

Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030. With the concerted efforts of the government and...

Sponsor: Kaohsiung Veterans General Hospital.Enrolling: 2708 locations